Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15413958 | 0.82 | ESR2 (0.60) | ESR2MEN1LMNAGAAKMT2A | |
| SCHEMBL10520096 | 0.82 | ESR2 (0.55) | ESR2MEN1LMNAGAAKMT2A | |
| SCHEMBL2572842 | 0.81 | CSNK2A1 (0.62) | ESR2MEN1LMNAGAAKMT2A | |
| SCHEMBL12050458 | 0.81 | ESR2 (0.53) | ESR2MEN1LMNAGAAKMT2A | |
| SCHEMBL31366931 | 0.81 | ESR2 (0.53) | ESR2MEN1LMNAGAAKMT2A | |
| SCHEMBL24093211 | 0.81 | ESR2 (0.53) | ESR2MEN1LMNAGAAKMT2A | |
| SCHEMBL9562370 | 0.81 | ESR2 (0.53) | ESR2MEN1LMNAGAAKMT2A | |
| SCHEMBL20750702 | 0.80 | ESR2 (0.53) | ESR2MEN1LMNAGAAKMT2A | |
| SCHEMBL21415408 | 0.79 | ESR2 (0.47) | ESR2PPARGPPARAHTR7RARB | |
| SCHEMBL24093362 | 0.78 | ESR2 (0.50) | ESR2MEN1LMNAGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1199301-B1 | Olefination process to itaconate and succinate derivatives | PFIZER LTD (GB) | 2005-06-08 | — | — | EP | claimed |
| US-20020188121-A1 | Novel olefination process to itaconate and succinate derivatives | DERRICK ANDREW MICHAEL (GB) | 2002-12-12 | — | — | US | claimed |
| US-6452041-B1 | REACTING ALDEHYDE OF FORMULA RCHO, OR A PROTECTED DERIVATIVE THEREOF SUCH AS A HEMIACETAL OR ADDUCT THEREOF SUCH AS A BISULPHITE, WITH A PHOSPHORUS COMPOUND TO OBTAIN SUCCINATE OR ITACONATE DERIVATIVE | PFIZER INC. | 2002-09-17 | — | — | US | claimed |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | PFIZER INC. | 2002-05-16 | — | — | US | claimed |
| EP-1199301-A1 | Olefination process to itaconate and succinate derivatives | Pfizer Limited (GB) | 2002-04-24 | — | — | EP | claimed |
| EP-1199301-B1 | Olefination process to itaconate and succinate derivatives | PFIZER LTD (GB) | 2005-06-08 | — | — | EP | disclosed |
| US-6750363-B2 | Olefination process to itaconate and succinate derivatives | PFIZER, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020188121-A1 | Novel olefination process to itaconate and succinate derivatives | DERRICK ANDREW MICHAEL (GB) | 2002-12-12 | — | — | US | disclosed |
| US-6452041-B1 | REACTING ALDEHYDE OF FORMULA RCHO, OR A PROTECTED DERIVATIVE THEREOF SUCH AS A HEMIACETAL OR ADDUCT THEREOF SUCH AS A BISULPHITE, WITH A PHOSPHORUS COMPOUND TO OBTAIN SUCCINATE OR ITACONATE DERIVATIVE | PFIZER INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
| EP-1199301-A1 | Olefination process to itaconate and succinate derivatives | Pfizer Limited (GB) | 2002-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188121-A1 | Novel olefination process to itaconate and succinate derivatives | HOGA1, OGDH, HADHA | ESR2 1899/4885MEN1 3498/4885LMNA 4684/4885 |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | HOGA1, HADHA, OGDH | ESR2 3015/4885MEN1 3506/4885LMNA 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.